Sepracor withdraws Lunivia EU filing
This article was originally published in Scrip
Sepracor has withdrawn the EU marketing application for its insomnia drug, Lunivia (eszopiclone) 2mg and 3mg tablets, as a result of the CHMP maintaining its recommendation that Lunivia should not be regarded as a new active substance.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.